News
-
Sandoz has received Danish marketing authorization for the AirFluSal Forspiro inhaler for the treatment of asthma and/or COPD in 50-250µg and 50-500µg versions. Sandoz acquired European rights to the product (formerly known as VR-315) from… Read more . . .
-
The FDA has announced the approval of GSK and Theravance’s Anoro Ellipta umeclidinium/vilanterol inhalation powder for the treatment of COPD. The approval triggers a $30 million milestone payment from Theravance to GSK. Theravance will pay… Read more . . .
-
Mylan has announced that it has acquired “exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications” from Pfizer, along with “multi-dose dry powder inhaler technology.” The… Read more . . .
-
A study published online December 15, 2013 in Nature Medicine shows that mice allowed to become obese develop specific immune system changes leading to airway hyper-reactivity. Researchers at Boston Children’s Hospital found that mice fed… Read more . . .
-
FLUIDDA has announced that it will meet with the FDA on January 17, 2014 to present its Functional Respiratory Imaging (FRI) technology for screening respiratory drugs. The FDA is evaluating FRI as part of its… Read more . . .
-
Fresenius Kabi USA has announced the availability of 10 ml vials of 20% acetylcysteine inhalation solution. Acetylcysteine inhalation solution has been on the FDA’s drug shortage lists since 2011, in part due to a shutdown… Read more . . .
-
Asmacure has started enrolling patients for a Phase 2 trial of its ASM-024 inhalation powder in patients with moderate and severe COPD, the company has announced. The company said that it has also completed dosing… Read more . . .
-
DDL24 concluded on Friday, December 13 with a half day of presentations and the final exhibition session. Bo Olsson of AstraZeneca kicked off the morning with a talk titled, “Validation of a General In Vitro… Read more . . .
-
Retrophin has taken several steps toward development of intranasal oxytocin for the treatment of schizophrenia and autism, the company has announced. The biopharmaceutical company says that it will acquire Kyalin Biosciences and its lead product,… Read more . . .
-
The second day of DDL 24 opened with a posters on the podium session featuring the finalists for the 2013 Pat Burnell New Investigator Award. The six presenters were: Eva Faulhammer, Technical University, Austria: “Effect… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK